TP53 and leukoencephalopathy with calcifications and cysts: Under the 2015 WHO criteria, we also observed that LCC patients only presented TP53 and KRAS mutations in the 46 gene panel, while non-LCC patients showed 8 additional mutations in genes other than TP53 and KRAS (LCC vs non-LCC = 2/46 vs 10/46, respectively).